Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2021

View Archived Issues

Aryl guanidine derivatives for invasive fungal infections found thanks to new mechanism of action

Mycobacterium tuberculosis inhibits the NLRP3 inflammasome through PknF to escape host immunity

New pyrimidinone amides as APJ receptor agonists identified for heart failure

Study elucidates how ApoE4 astrocytes influence neuronal amyloidosis

Altered Chkb leads to cardiomyopathy, murine model shows

Discovery of novel potent pan-serotypic dengue antivirals

Lilly identifies new ketohexokinase inhibitors

Glucocorticoid receptor agonist ADCs patented by AbbVie

Shanghai Meiyue Biotech Development divulges transcription factor PU.1 inhibitors

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

[11C]PDE7-136 as new PET neuroimaging candidate

HEC-866, a novel pirfenidone analogue with improved therapeutic efficacy in models of IPF

GeneQuantum and BrightGene collaborate on development of antibody immune agonist conjugate GQ-1007

BI-1265162, an inhaled ENaC inhibitor for the mutation-agnostic treatment of cystic fibrosis

University of Minho chromene compound induces apoptosis in breast cancer cells

New cytochrome P450 1B1 inhibitors identfied at the University of Kentucky

IRF5 inhibition suppresses lupus-like disease in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...